Voyager Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 162

Employees

  • Stock Symbol
  • VYGR

Stock Symbol

  • Share Price
  • $4.23
  • (As of Friday Closing)

Voyager Therapeutics General Information

Description

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 75 Hayden Avenue
  • Lexington, MA 02421
  • United States
+1 (857)
Primary Industry
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 75 Hayden Avenue
  • Lexington, MA 02421
  • United States
+1 (857)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Voyager Therapeutics Stock Performance

As of 14-Feb-2025, Voyager Therapeutics’s stock price is $4.23. Its current market cap is $231M with 54.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.23 $4.38 $4.00 - $10.66 $231M 54.6M 429K $0.70

Voyager Therapeutics Financials Summary

As of 30-Sep-2024, Voyager Therapeutics has a trailing 12-month revenue of $164M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (5,060) 139,410 127,637 26,625
Revenue 163,784 250,008 40,907 37,415
EBITDA 14,350 126,458 (41,993) (65,642)
Net Income 25,880 132,330 (46,408) (71,197)
Total Assets 426,041 351,281 159,356 193,855
Total Debt 45,347 20,293 23,126 44,179
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Voyager Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Voyager Therapeutics‘s full profile, request access.

Request a free trial

Voyager Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering
Biotechnology
Lexington, MA
162 As of 2023

Rockville, MD
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Voyager Therapeutics Competitors (58)

One of Voyager Therapeutics’s 58 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Anokion Venture Capital-Backed Ecublens, Switzerland
Forge Biologics Formerly VC-backed Grove City, OH
NexImmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 58 competitors. Get the full list »

Voyager Therapeutics Patents

Voyager Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240391988-A1 Tau binding compounds Pending 15-Sep-2022
AU-2023320453-A1 Compositions and methods for crossing the blood brain barrier Pending 03-Aug-2022
AU-2023279090-A1 Aav capsid variants and uses thereof Pending 02-Jun-2022
AU-2023217698-A1 Aav capsid variants and uses thereof Pending 08-Feb-2022
EP-4476241-A1 Aav capsid variants and uses thereof Pending 08-Feb-2022 C07K14/005
To view Voyager Therapeutics’s complete patent history, request access »

Voyager Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Voyager Therapeutics ESG

Risk Overview

Risk Rating

Updated January, 20, 2020

41.94 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,042

Rank

Percentile

Pharmaceuticals

Industry

of 947

Rank

Percentile

Biotechnology

Subindustry

of 427

Rank

Percentile

To view Voyager Therapeutics’s complete esg history, request access »

Voyager Therapeutics FAQs

  • When was Voyager Therapeutics founded?

    Voyager Therapeutics was founded in 2013.

  • Where is Voyager Therapeutics headquartered?

    Voyager Therapeutics is headquartered in Lexington, MA.

  • What is the size of Voyager Therapeutics?

    Voyager Therapeutics has 162 total employees.

  • What industry is Voyager Therapeutics in?

    Voyager Therapeutics’s primary industry is Biotechnology.

  • Is Voyager Therapeutics a private or public company?

    Voyager Therapeutics is a Public company.

  • What is Voyager Therapeutics’s stock symbol?

    The ticker symbol for Voyager Therapeutics is VYGR.

  • What is the current stock price of Voyager Therapeutics?

    As of 14-Feb-2025 the stock price of Voyager Therapeutics is $4.23.

  • What is the current market cap of Voyager Therapeutics?

    The current market capitalization of Voyager Therapeutics is $231M.

  • What is Voyager Therapeutics’s current revenue?

    The trailing twelve month revenue for Voyager Therapeutics is $164M.

  • Who are Voyager Therapeutics’s competitors?

    Regenxbio, Intellia Therapeutics, Anokion, Forge Biologics, and NexImmune are some of the 58 competitors of Voyager Therapeutics.

  • What is Voyager Therapeutics’s annual earnings per share (EPS)?

    Voyager Therapeutics’s EPS for 12 months was $0.70.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »